Cilazapril

• Description:

  Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113) . Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure[1][2][3][4][5].

• Product Name Alternative:

  Ro 31-2848

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H312-H332

• Target:

  Angiotensin-converting Enzyme (ACE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/cilazapril.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@@H]1CCCN2N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)CCC2)=O)O

• Molecular Formula:

  C22H31N3O5

• Molecular Weight:

  417.50

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

• References & Citations:

  [1]Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24.|[2]Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9 (1) : p. 39-44.|[3]Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2 (Suppl 2) :139S-150S.|[4]Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64 (3) :PL27-39.|[5]Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11 (11) :1009-15.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [88768-40-5]